NO20073039L - Kontrastmidler - Google Patents

Kontrastmidler

Info

Publication number
NO20073039L
NO20073039L NO20073039A NO20073039A NO20073039L NO 20073039 L NO20073039 L NO 20073039L NO 20073039 A NO20073039 A NO 20073039A NO 20073039 A NO20073039 A NO 20073039A NO 20073039 L NO20073039 L NO 20073039L
Authority
NO
Norway
Prior art keywords
contrast agents
biomodifier
areas
human
general formula
Prior art date
Application number
NO20073039A
Other languages
English (en)
Norwegian (no)
Inventor
Dagfinn Lovhaug
Morten Eriksen
Hege B Fjerdingstad
Andrew Healey
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Priority to NO20073039A priority Critical patent/NO20073039L/no
Publication of NO20073039L publication Critical patent/NO20073039L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
NO20073039A 2004-11-22 2007-06-14 Kontrastmidler NO20073039L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20073039A NO20073039L (no) 2004-11-22 2007-06-14 Kontrastmidler

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (fr) 2004-11-22 2005-11-21 Agents de contraste
NO20073039A NO20073039L (no) 2004-11-22 2007-06-14 Kontrastmidler

Publications (1)

Publication Number Publication Date
NO20073039L true NO20073039L (no) 2007-08-16

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073039A NO20073039L (no) 2004-11-22 2007-06-14 Kontrastmidler

Country Status (17)

Country Link
US (1) US8182790B2 (fr)
EP (2) EP1814598B1 (fr)
JP (2) JP5116480B2 (fr)
KR (1) KR20070091609A (fr)
CN (1) CN101107016B (fr)
AT (1) ATE494913T1 (fr)
AU (1) AU2005307195A1 (fr)
BR (1) BRPI0518328A2 (fr)
CA (1) CA2586621A1 (fr)
DE (1) DE602005025911D1 (fr)
ES (1) ES2358745T3 (fr)
IL (1) IL182898A0 (fr)
MX (1) MX2007006050A (fr)
NO (1) NO20073039L (fr)
RU (1) RU2007118385A (fr)
WO (1) WO2006054904A2 (fr)
ZA (1) ZA200705043B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US20100233082A1 (en) * 2006-08-28 2010-09-16 Bengt Langstrom 68GA-Labeled Peptide-Based Radiopharmaceuticals
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
WO2009074628A1 (fr) * 2007-12-13 2009-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, polypeptides cycliques et produit pharmaceutique les comportant pour l'imagerie spécifique non invasive de fibrose
CA2749108C (fr) * 2008-01-18 2017-06-27 Visen Medical, Inc. Agents d'imagerie fluorescents fractionnes intramoleculairement
JP5265762B2 (ja) 2008-05-13 2013-08-14 ユニバーシティ・オブ・カンザス 金属抽出ペプチド（ｍａｐ）タグおよび関連する方法
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
US9187735B2 (en) 2012-06-01 2015-11-17 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
EP3077009A4 (fr) * 2013-12-03 2017-06-14 The General Hospital Corporation Sondes d'imagerie moléculaire

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
WO1989010758A1 (fr) 1988-05-02 1989-11-16 Zynaxis Technologies, Inc. Composes, compositions et procede de liaison de substances de bio-affection sur des membranes superficielles de bio-particules
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
AU3221993A (en) 1991-11-27 1993-06-28 Phanos Technologies, Inc. Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
WO1998018500A2 (fr) 1996-10-28 1998-05-07 Marsden, John, Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
WO1998032469A2 (fr) * 1997-01-29 1998-07-30 Nycomed Imaging As Polymeres
CA2297216C (fr) 1997-07-28 2008-02-05 Nycomed Amersham Plc Colorants de cyanine
US5942637A (en) 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
ES2322723T5 (es) * 1998-05-08 2013-03-11 The Regents Of The University Of California Métodos para detectar e inhibir la angiogénesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
KR100866666B1 (ko) * 2000-04-12 2008-11-04 지이 헬스케어 에이에스 펩티드 기재 화합물
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
JP2005506952A (ja) 2000-11-27 2005-03-10 ブリストル−マイヤーズ・スクイブ・メディカル・イメージング・インコーポレイテッド 心臓潅流およびビトロネクチンレセプター標的造影剤の同時造影
RU2303042C2 (ru) 2001-07-10 2007-07-20 Джи-И Хелткер АС Соединения на основе пептидов для направленной доставки к рецепторам интегринов
GB0116815D0 (en) * 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
US20050255182A1 (en) 2002-06-17 2005-11-17 Cartela Ab Methods and uses of the integrin alpha 10 chain, for preventing progression of atherosclerosis plaque formation
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019247A2 (fr) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Compositions de peptides cycliques et de composes d'imagerie, et utilisations en imagerie et en therapie ciblees
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
EP1729823B1 (fr) * 2004-03-04 2009-11-04 GE Healthcare AS Conjugues comprenant analogues peptidiques d'angiotensin et agents de chelation pour la therapie et le diagnostic
RU2393167C2 (ru) * 2004-06-16 2010-06-27 Джи-И Хелткер АС Пептидные соединения
JP5280682B2 (ja) 2004-06-16 2013-09-04 ジーイー・ヘルスケア・アクスイェ・セルスカプ ペプチド系化合物

Also Published As

Publication number Publication date
ATE494913T1 (de) 2011-01-15
JP2008520658A (ja) 2008-06-19
IL182898A0 (en) 2007-08-19
BRPI0518328A2 (pt) 2008-11-11
EP1814598A2 (fr) 2007-08-08
JP2012207027A (ja) 2012-10-25
ES2358745T3 (es) 2011-05-13
ZA200705043B (en) 2008-09-25
US8182790B2 (en) 2012-05-22
US20090208412A1 (en) 2009-08-20
CN101107016A (zh) 2008-01-16
EP1814598B1 (fr) 2011-01-12
DE602005025911D1 (de) 2011-02-24
EP2243496A2 (fr) 2010-10-27
CA2586621A1 (fr) 2006-05-26
RU2007118385A (ru) 2008-12-27
MX2007006050A (es) 2007-11-14
JP5116480B2 (ja) 2013-01-09
WO2006054904A3 (fr) 2007-04-05
CN101107016B (zh) 2011-11-16
WO2006054904A2 (fr) 2006-05-26
EP2243496A3 (fr) 2012-12-26
KR20070091609A (ko) 2007-09-11
AU2005307195A1 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
NO20073039L (no) Kontrastmidler
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
DE60042522D1 (de) Cyanin- oder indocyaninefarbstoffe biokonjugate für biomedische anwendungen
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
CY1109151T1 (el) Αντισωματα dr4 και χρησεις αυτων
EP2269610A3 (fr) Dérivés hétérocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
DE69934337D1 (de) Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
DE60234057D1 (de) Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO1998018497A3 (fr) Agents de contraste
ATE314097T1 (de) Kontrastmittel
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
DE60326833D1 (de) Vitamin-mitomycin-konjugate
GB0421639D0 (en) Methods and compositions relating to alzheimer's disease
NO20052925D0 (no) Vannloselige anioniske bakterieklorofyllderivater og deres anvendelse
HUP0400904A2 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
BRPI0418552A (pt) compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas
ATE547009T1 (de) Zusammensetzungen und verfahren zur förderung von körperfettverlust
ATE376428T1 (de) Metallkomplexverbindungen
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
ATE425770T1 (de) Kontrastmittel
EP1611151A4 (fr) Peptides stq
WO2005049095A3 (fr) Agent de contraste
DE60206599D1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application